News Releases
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, Canada, April 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 28, 2024 – NervGen
NervGen Announces $20 Million Bought Deal Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 21, 2024 – NervGen
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, Canada, February 21, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment
NervGen Pharma Grants Stock Options
Vancouver, Canada, February 20, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
On track to complete enrollment of the chronic cohort in Q2 2024 Data readout from chronic cohort expected in Q3 2024 Planning underway to make
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on ‘Remarkable People’ Podcast Hosted by Tech Luminary Guy Kawasaki
Dr. Silver’s life work, culminating in NervGen’s NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Vancouver, Canada,
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
– Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs – Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with
NervGen Pharma Appoints John Ruffolo to Board of Directors
Extensive experience in private equity, venture capital and advising high growth, innovative companies Brings personal experience and knowledge of spinal cord injury to NervGen’s board
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, Canada, September 25,
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
Vancouver, Canada, September 11, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
Vancouver, Canada. September 5, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference
Vancouver, Canada. August 22, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the